FIGURE

Fig. 3

ID

ZDB-FIG-250822-58

Publication

Cakan-Akdogan et al., 2025 - Novel anti-VEGF scFv antibodies with superior in vitro and in vivo activities

Other Figures

All Figure Page

Back to All Figure Page

Fig. 3

Inhibitory activity of the scFv variants. A) Inhibition of VEGF induced HUVEC proliferation was tested with an MTT assay. Three variants were compared to the reference ranibizumab. B) VEGF induced VEGFR2 activity test with a VEGF bioassay kit was analyzed with normalized luminescence values for 9 different concentrations of anti-VEGFs. scFv1/2/3 variants and scFvWT were compared to bevacizumab, ranibizumab, brolucizumab. Bevacizumab (red), ranibizumab (green), brolucizumab (navy), scFvWT (gray), scFv1 (orange), scFv2 (blue), scFv3 (purple). IC50 was calculated after 4PL fitting of log(molarity) vs. the absorbance values, using GraphPad Prism (version 8.0.1, GraphPad Software, Boston, Massachusetts USA).

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Sci. Rep.